𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non–ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial

✍ Scribed by David A. Morrow; Benjamin M. Scirica; Ewa Karwatowska-Prokopczuk; Allan Skene; Carolyn H. McCabe; Eugene Braunwald

Book ID
116190488
Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
203 KB
Volume
151
Category
Article
ISSN
1097-6744

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Early Glycoprotein IIb/IIIa Inhibiti
The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—Study design and rationale
✍ Robert P. Giugliano; L. Kristin Newby; Robert A. Harrington; C. Michael Gibson; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 148 KB